Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
SLK
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "SLK" in MCE Product Catalog:
4
4 Cited Publications
Target:
Research Areas:
SLK/STK10-IN-1 is a potent and selective inhibitor of SLK and STK10 with antitumor activity.
1
1 Cited Publications
Target:
Research Areas:
Bisindolylmaleimide III is a protein kinase C (PKC) inhibitor with IC50 values of 0.26, 5.7, and 6 μM against PKCα, PKCδ, and PKCμ, respectively. Bisindolylmaleimide III also exhibits inhibitory activity against other off-targets, with IC50 values of 0.17, 1, and 2 μM against SLK, adenosine kinase (AK), and CDK2, respectively; its Ki for NQO2 is 16.5 μM. Bisindolylmaleimide III selectively binds to activated Rsk1 following EGF stimulation, and serves as a tool for detecting the activation status of intracellular Rsk1 and PKCα, as well as for functional analysis of SLK. Bisindolylmaleimide III can be used in studies of signal transduction and colorectal cancer .
K00546 is a potent CDK1 and CDK2 inhibitor with IC50s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC50s of 8.9 nM and 29.2 nM, respectively .
TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, with an IC50 of 13 nM. TAS0728 also shows IC50s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for BMX、HER4、BLK、EGFR、JAK3、SLK and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of HER2, HER3, and downstream effectors .
Cat. No.: HY-RS13379
Target:
Research Areas:
SLK Human Pre-designed siRNA Set A contains three designed siRNAs for SLK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS17069
Target:
Research Areas:
Slk Mouse Pre-designed siRNA Set A contains three designed siRNAs for Slk gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS23513
Target:
Research Areas:
Slk Rat Pre-designed siRNA Set A contains three designed siRNAs for Slk gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS05174
Target:
Research Areas:
FYN Human Pre-designed siRNA Set A contains three designed siRNAs for FYN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-150782
CAS No.: 2676156-05-9
UNC-CA359 is a potent epidermal growth factor receptor (EGFR) inhibitor, with an IC50 value of 18 nM. UNC-CA359 exhibits strong anti-tumor activity, can be used to Chordoma research . UNC-CA359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-112454
CAS No.: 683775-59-9
Target:
Research Areas:
Bisindolylmaleimide III hydrochloride is a protein kinase C (PKC) inhibitor with IC50 values of 0.26, 5.7, and 6 μM against PKCα, PKCδ, and PKCμ, respectively. Bisindolylmaleimide III hydrochloride also exhibits inhibitory activity against other off-targets, with IC50 values of 0.17, 1, and 2 μM against SLK, adenosine kinase (AK), and CDK2, respectively; its Ki for NQO2 is 16.5 μM. Bisindolylmaleimide III hydrochloride selectively binds to activated Rsk1 following EGF stimulation, and serves as a tool for detecting the activation status of intracellular Rsk1 and PKCα, as well as for functional analysis of SLK. Bisindolylmaleimide III hydrochloride can be used in studies of signal transduction and colorectal cancer .
Cat. No.: HY-178974
Target:
Research Areas:
SLK/STK10-IN-2 (Compound 23) is a highly selective STK10 inhibitor, with a Kd of 365 nM and an IC50 of 0.85 μM. SLK/STK10-IN-2 exhibits EC50 of 0.89 μM in NanoBRET cell experiments. SLK/STK10-IN-2 shows no significant binding to SLK, STK3/4. SLK/STK10-IN-2 can be used to study STK10-related diseases (such as abnormal lymphocyte migration) .
Cat. No.: HY-P702727
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: FYN; FYN oncogene related to SRC, FGR, YES; tyrosine-protein kinase Fyn; MGC45350; SLK; SYN; src-like kinase; proto-oncogene Syn; c-syn protooncogene; proto-oncogene c-Fyn; src/yes-related novel; tyrosine kinase p59fyn(T); OKT3-induced calcium influx regulator; p59-FYN
Species:
Source:
Cat. No.: HY-103647R
CAS No.: 443798-47-8
Target:
Research Areas:
K00546 (Standard) is the analytical standard of K00546 (HY-103647). This product is intended for research and analytical applications. K00546 is a potent CDK1 and CDK2 inhibitor with IC50s of 0.6 nM and 0.5 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. K00546 is also a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC50s of 8.9 nM and 29.2 nM, respectively .
Cat. No.: HY-P85545
Synonyms: C syn protooncogene; Fyn; FYN oncogene related to SRC FGR YES; FYN_HUMAN; MGC45350; OKT3 induced calcium influx regulator; P59 FYN; p59-Fyn; Protein tyrosine kinase fyn; Proto oncogene tyrosine protein kinase fyn; Proto-oncogene c-Fyn; Proto-oncogene Syn; Protooncogene Syn; SLK; Src like kinase; Src yes related novel gene; Src-like kinase; Src/yes related novel; Src/yes related novel gene; SYN; Tyrosine kinase p59fyn T; Tyrosine kinase p59fyn; T; Tyrosine-protein kinase Fyn.
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
